• Profile
Close

Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe renal disease

Journal of the American Society of Nephrology Aug 26, 2020

Moura MC, Irazabal MV, Eirin A, et al. - Since treatment of cases of ANCA-associated vasculitis (AAV) and severe renal involvement is not established, therefore, researchers undertook this retrospective cohort study to define results in response to rituximab (RTX) vs cyclophosphamide (CYC) and plasma exchange (PLEX). This study involved MPO- or PR3-ANCA–positive patients with AAV (MPA and GPA) and severe renal disease (eGFR <30 ml/min per 1.73 m2). Experts compared remission, relapse, ESKD as well as mortality following remission-induction with CYC or RTX, with or without the use of PLEX. eGFR <15 ml/min per 1.73 m2 at diagnosis, renal recovery and renal remission at 6 months, all were identified as predictors for ESKD and/or death at 18 months. According to the findings, for the treatment of patients with AAV and severe renal disease, the apparent advantages and risks of using CYC or RTX were balanced. In this cohort, findings demonstrated no benefit of the addition of PLEX to standard remission-induction therapy.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay